Free Trial

Axsome Therapeutics (AXSM) SEC Filings & 10K Form

Axsome Therapeutics logo
$104.35 -1.41 (-1.33%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$104.24 -0.11 (-0.11%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Axsome Therapeutics SEC Filings

DateFilerForm TypeView
05/20/2025
8:46 PM
Axsome Therapeutics (Issuer)
Coleman Mark (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2025
4:54 PM
Axsome Therapeutics (Subject)
Coleman Mark (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/15/2025
7:09 AM
Axsome Therapeutics (Subject)
RTW INVESTMENTS, LP (Filed by)
Form SCHEDULE 13G/A
05/13/2025
6:06 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/05/2025
3:47 PM
Axsome Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/05/2025
6:33 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/25/2025
3:31 PM
Axsome Therapeutics (Filer)
Form DEF 14A
04/25/2025
3:32 PM
Axsome Therapeutics (Filer)
Form DEFA14A
04/25/2025
3:33 PM
Axsome Therapeutics (Filer)
Form ARS
04/01/2025
6:06 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/25/2025
6:06 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2025
6:05 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/03/2025
6:06 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/25/2025
6:56 PM
Axsome Therapeutics (Issuer)
Murdock Hunter R. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2025
6:57 PM
Axsome Therapeutics (Issuer)
Maizel Ari (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2025
6:59 PM
Axsome Therapeutics (Issuer)
Saad Mark E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2025
7:00 PM
Axsome Therapeutics (Issuer)
JEFFS ROGER (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2025
7:02 PM
Axsome Therapeutics (Issuer)
Mahony Susan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2025
6:51 PM
Axsome Therapeutics (Issuer)
TABUTEAU HERRIOT (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2025
6:53 PM
Axsome Therapeutics (Issuer)
Jacobson Mark L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/25/2025
6:54 PM
Axsome Therapeutics (Issuer)
Pizzie Nick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2025
6:06 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2025
8:20 PM
Axsome Therapeutics (Issuer)
Pizzie Nick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2025
8:00 AM
Axsome Therapeutics (Subject)
RTW INVESTMENTS, LP (Filed by)
Form SCHEDULE 13G/A
02/10/2025
6:06 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2025
6:05 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/30/2024
6:56 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/26/2024
6:05 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/12/2024
8:43 AM
Axsome Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/24/2024
5:23 PM
Axsome Therapeutics (Issuer)
Maizel Ari (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
10/01/2024
4:24 PM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/11/2024
6:00 PM
Axsome Therapeutics (Issuer)
Saad Mark E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/11/2024
3:32 PM
Axsome Therapeutics (Subject)
Saad Mark E (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/04/2024
6:05 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/21/2024
6:05 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/09/2024
6:27 PM
Axsome Therapeutics (Issuer)
Jacobson Mark L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/05/2024
6:05 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2024
3:30 PM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2024
3:30 PM
Axsome Therapeutics (Issuer)
Saad Mark E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2024
3:31 PM
Axsome Therapeutics (Issuer)
JEFFS ROGER (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2024
3:31 PM
Axsome Therapeutics (Issuer)
Coleman Mark (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Here’s How to Claim Your Stake in Elon’s Private Company, xAI (Ad)

I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.

All the details are waiting for you now — but you need to act before the May 1st funding window clos
06/11/2024
3:32 PM
Axsome Therapeutics (Issuer)
Mahony Susan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
6:38 AM
Axsome Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/29/2024
7:11 PM
Axsome Therapeutics (Issuer)
Axsome Therapeutics (Issuer)
Coleman Mark (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2024
7:12 PM
Axsome Therapeutics (Issuer)
Axsome Therapeutics (Issuer)
Jacobson Mark L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2024
3:28 PM
Axsome Therapeutics (Subject)
Coleman Mark (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:AXSM) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners